Core Insights - The global biopharmaceutical industry is entering a rapid development phase, with accelerated technological iterations in cutting-edge fields such as antibody drugs, cell and gene therapy, and radiolabeled drug conjugates (RDC) [1] - Domestic policies are increasingly supporting innovative drug research and the standardization of quality control, presenting new opportunities for industry growth [1] Conference Highlights - Comprehensive coverage of five core biopharmaceutical areas: antibody/protein drugs, cell and gene therapy, nucleic acid drugs, peptide drugs, and RDC, addressing the entire "research and development - quality control" chain [2] - Over 25 top experts from industry and academia will participate, including R&D and quality control directors, renowned professors, and clinical department heads, fostering deep integration of industry, academia, and clinical practice [2] - All presentations will focus on core technologies and practical methods, utilizing real case studies to address technical challenges and solutions, enhancing attendees' ability to apply these methods in their work [2] Conference Details - The conference will take place from March 24 to 26, 2026, organized by the Instrument Information Network, with support from key laboratories and professional committees [4] Agenda Overview - The agenda includes specialized sessions on various topics such as antibody drug conjugation techniques, nucleic acid drug development, and quality control in cell and gene therapy, featuring presentations from leading experts in the field [5][6][7]

Group 1: Rise of RDC Drugs - The development of Radiopharmaceutical Drug Conjugates (RDC) is gaining momentum in the field of oncology, driven by the need for more precise, effective, and less toxic treatment methods [1][2] - The history of radioactive substances in medicine dates back to 1896, with significant advancements in nuclear medicine applications, particularly in diagnostics, which dominate over 90% of the market [2] - Traditional nuclear medicines like Iodine-131 and Radium-223 have been widely used in clinical treatments, with Iodine-131 being effective for thyroid conditions since 1941 and Radium-223 approved by the FDA in 2013 for prostate cancer bone metastases [2] Group 2: Mechanism and Composition of RDC - RDCs combine targeting molecules with radioactive isotopes to create a new type of integrated diagnostic and therapeutic drug, allowing for precise localization of diseased tissues and simultaneous treatment [7][10] - The key components of RDC include targeting ligands, linkers, chelators, and radioactive isotopes, each serving specific functions to ensure effective delivery and action against cancer cells [9][10] - The unique ability of RDCs to integrate diagnosis and treatment makes them a versatile tool in clinical applications, with common isotopes used for diagnosis being Gallium-68 and for treatment being Lutetium-177 [10] Group 3: Global R&D Landscape of RDC - The RDC sector has seen significant R&D achievements, with 11 RDC drugs currently on the market, including 9 diagnostic and 2 therapeutic agents, focusing on targets like PSMA and SSTR for prostate and neuroendocrine tumors [11][12] - Novartis leads the international market with strategic acquisitions, including AAA and Endocyte, resulting in flagship products Lutathera and Pluvicto, with Pluvicto projected to achieve $1.392 billion in sales by 2024 [12][16] - Other major pharmaceutical companies such as Roche, Eli Lilly, Bayer, and AstraZeneca are investing heavily in RDC development, each committing over $1 billion to find promising pipelines [16] Group 4: Domestic Market Dynamics in China - Over 120 Chinese companies are involved in RDC R&D, with leading firms like Yuan Da Pharmaceutical developing innovative products targeting various cancers [17] - Heng Rui Pharmaceutical is also a key player with multiple pipelines, including three RDCs in Phase III clinical trials, targeting PSMA and SSTR [17][18] - New entrants like Xiantong Pharmaceutical and Yunhe Pharmaceutical are emerging, with innovative products entering clinical trials, indicating a growing competitive landscape in the domestic RDC market [20][23]